1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893–962.
2. Sanna T, Diener H-C, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 Jun 26;370(26):2478–86.
3. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation.
2014 Feb 25;129(8):837–47.
4. La fibrillation atriale : données démographiques - Réalités Cardiologiques [Internet]. [cited 2018 Feb 2]. Available from: https://www.realites-cardiologiques.com/2010/03/31/la-fibrillation-atriale-donnees-demographiques/
5. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med.
1995 Mar 13;155(5):469–73.
6. Lip GYH, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med.
2010 Jun;123(6):484–8.
7. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation:
the Euro Heart Survey. Chest. 2010 Nov;138(5):1093–100.
8. Linkins L-A, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med.
2003 Dec 2;139(11):893–900.
9. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999 Oct 5;131(7):492–
501.
10. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun
19;146(12):857–67.
11. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated.
Stroke. 2009 Jan;40(1):235–40.
12. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep
17;361(12):1139–51.
13. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus
14. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet Lond Engl. 2014 Mar 15;383(9921):955–62.
15. O’Brien EC, Simon DN, Allen LA, Singer DE, Fonarow GC, Kowey PR, et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014 Oct;168(4):487–94.
16. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755–9.
17. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA.
2014 Nov 19;312(19):1988–98.
18. Belgaid DR, Khan Z, Zaidi M, Hobbs A. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. Int J Cardiol. 2016 Sep 15;219:177–9.
19. Park J-W, Bethencourt A, Sievert H, Santoro G, Meier B, Walsh K, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2011 Apr 1;77(5):700–6.
20. Guérios EE, Schmid M, Gloekler S, Khattab AA, Wenaweser PM, Windecker S, et al. Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation.
Arq Bras Cardiol. 2012 Jun;98(6):528–36.
21. Nietlispach F, Gloekler S, Krause R, Shakir S, Schmid M, Khattab AA, et al. Amplatzer left atrial appendage occlusion: single center 10-year experience. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2013 Aug 1;82(2):283–9.
22. Haute Autorité de Santé - Prise en charge des surdosages, des situations à risque
hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier [Internet]. [cited 2018 Feb 11]. Available from:
https://www.has-sante.fr/portail/jcms/c_682188/fr/prise-en-charge-des-surdosages-des- situations-a-risque-hemorragique-et-des-accidents-hemorragiques-chez-les-patients-traites-par-antivitamines-k-en-ville-et-en-milieu-hospitalier
23. Masoudi FA, Calkins H, Kavinsky CJ, Slotwiner DJ, Turi ZG, Drozda JP, et al. 2015
ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview: A professional societal overview from the American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2015 Nov;86(5):791–807.
24. Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol. 2008 Sep 9;52(11):924–9.
25. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012 Jun;33(12):1500–10.
26. Bureau M-L, Liuu E, Christiaens L, Pilotto A, Mergy J, Bellarbre F, et al. Using a
multidimensional prognostic index (MPI) based on comprehensive geriatric assessment (CGA) to predict mortality in elderly undergoing transcatheter aortic valve implantation.
Int J Cardiol. 2017 Jun 1;236:381–6.
27. Forcillo J, Condado JF, Ko Y-A, Yuan M, Binongo JN, Ndubisi NM, et al. Assessment of Commonly Used Frailty Markers for High- and Extreme-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2017 Dec;104(6):1939–46.
28. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002 Jul 23;59(2):193–7.
29. Arrêté du 12 mai 2016 limitant la pratique de l’acte de « fermeture de l’appendice auriculaire gauche par voie transcutanée » à certains établissements de santé en
application des dispositions de l’article L. 1151-1 du code de santé publique | Legifrance [Internet]. [cited 2018 Feb 22]. Available from:
https://www.legifrance.gouv.fr/eli/arrete/2016/5/12/AFSH1612533A/jo/texte
30. Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without
contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017 Sep;14(9):1302–8.
31. Jalal Z, Dinet M-L, Combes N, Pillois X, Renou P, Sibon I, et al. Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes. Arch Cardiovasc Dis. 2017 Apr;110(4):242–9.
32. Holmes DR, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol. 2015 Jun 23;65(24):2614–23.
33. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol.
2017 Dec 19;70(24):2964–75.
34. Santoro G, Meucci F, Stolcova M, Rezzaghi M, Mori F, Palmieri C, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2016 Feb;11(10):1188–94.
35. Viles-Gonzalez JF, Kar S, Douglas P, Dukkipati S, Feldman T, Horton R, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol. 2012 Mar 6;59(10):923–9.
36. Raphael CE, Friedman PA, Saw J, Pislaru SV, Munger TM, Holmes DR. Residual leaks following percutaneous left atrial appendage occlusion: assessment and management implications. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol.
2017 Nov 20;13(10):1218–25.
37. Boersma LVA, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016 Aug;37(31):2465–74.
38. Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2016 Feb;11(10):1170–9.
39. Weise FK, Bordignon S, Perrotta L, Konstantinou A, Bologna F, Nagase T, et al. Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2018 Feb 6;
40. Lempereur M, Aminian A, Freixa X, Gafoor S, Kefer J, Tzikas A, et al. Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2017 Nov 1;90(5):E111–21.